PAM
FPRX

Paradigm Asset Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Paradigm Asset Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-8,200
Closed -$247K – 544
2017
Q2 		$247K Sell
8,200
-8,500
-51% -$265K 0.05% 329
2017
Q1 		$604K Buy
16,700
+14,700
+735% +$648K 0.11% 221
2016
Q4 		$100K Sell
2,000
-100
-5% -$5.25K 0.02% 411
2016
Q3 		$110K Buy
+2,100
New +$100K 0.02% 399

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Paradigm Asset Management's FPRX Position: Q3 2017 in Review

Paradigm Asset Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q3 2017, closing a stake of 8,200 shares — an estimated $247K sold.

Paradigm Asset Management first reported a position in FPRX in Q3 2016 and held it in 4 quarters. The position peaked at $604K in Q1 2017. 126 funds tracked by Wall St. Rank hold FPRX as of Q3 2017.

  • Paradigm Asset Management reported no remaining Five Prime Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Paradigm Asset Management sold 8,200 Five Prime Therapeutics, Inc. shares in Q3 2017, an estimated $247K.
  • Paradigm Asset Management first reported a position in Five Prime Therapeutics, Inc. in Q3 2016 and held it in 4 quarters.
  • Paradigm Asset Management's Five Prime Therapeutics, Inc. position peaked at $604K in Q1 2017.
  • 126 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2017.

Based on Paradigm Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.